Type 2 Diabetes Mellitus Completed Phase 3 Trials for Pioglitazone (DB01132)

Back to Type 2 Diabetes Mellitus

Also known as: Non-Insulin-Dependent Diabetes Mellitus / Type 2 Diabetes Mellitus (T2DM) / Type 2 Diabetes / Diabetes, Type II / Type II Diabetes Mellitus / T2DM / Type Two Diabetes Mellitus / Diabetes mellitus non-insulin-dependent / NIDDM / Diabetes mellitus: [adult onset] or [noninsulin dependent] / Diabetes mellitus type 2 (disorder) / Diabetes mellitus: [adult onset, with no mention of complication] or [maturity onset] or [non-insulin dependent] / Diabetes Mellitus, Type 2 / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

Indication	Status	Phase
DBCOND0029752 (Type 2 Diabetes Mellitus)	Completed	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00220961	Actos Now for Prevention of Diabetes (ACT NOW)	Prevention	Pioglitazone (DB01132)
NCT00680745	Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients	Treatment	Dapagliflozin (DB06292) Glimepiride (DB00222) Metformin (DB00331) Pioglitazone (DB01132) Rosiglitazone (DB00412)
NCT00683878	Add-on to Thiazolidinedione (TZD) Failures	Treatment	2,4-thiazolidinedione (DB11898) Dapagliflozin (DB06292) Pioglitazone (DB01132)
NCT01095666	A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone	Treatment	Dapagliflozin (DB06292) Metformin (DB00331) Pioglitazone (DB01132)
NCT00086515	Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00094757	An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)	Treatment	Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT01289119	Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes	Treatment	Alogliptin (DB06203) Metformin (DB00331) Pioglitazone (DB01132)
NCT00106704	Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)	Treatment	Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00295633	A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Rosiglitazone (DB00412) Saxagliptin (DB06335)
NCT01183013	30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks	Treatment	Linagliptin (DB08882) Pioglitazone (DB01132)
NCT01064687	A Study in Participants With Type 2 Diabetes Mellitus	Treatment	Dulaglutide (DB09045) Exenatide (DB01276) Metformin (DB00331) Pioglitazone (DB01132)
NCT00744367	A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Taspoglutide (DB14027)
NCT00328393	Effect of Pioglitazone on Ambulatory Blood Pressure	Treatment	Pioglitazone (DB01132)
NCT00839527	A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes	Treatment	Albiglutide (DB09043) Glimepiride (DB00222) Metformin (DB00331) Pioglitazone (DB01132)
NCT00909597	A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes	Treatment	Pioglitazone (DB01132) Taspoglutide (DB14027)
NCT00763815	GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone	Treatment	Lixisenatide (DB09265) Metformin (DB00331) Pioglitazone (DB01132)
NCT00097279	Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes	Treatment	Insulin aspart (DB01306) Metformin (DB00331) Pioglitazone (DB01132)
NCT00099853	Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes	Treatment	Pioglitazone (DB01132) Vildagliptin (DB04876)
NCT01106690	The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)	Treatment	Canagliflozin (DB08907) Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00000620	Action to Control Cardiovascular Risk in Diabetes (ACCORD)	Prevention	Acarbose (DB00284) Amlodipine (DB00381) Benazepril (DB00542) Candesartan cilexetil (DB00796) Carvedilol (DB01136) Chlorthalidone (DB00310) Diltiazem (DB00343) Felodipine (DB01023) Fenofibrate (DB01039) Furosemide (DB00695) Glimepiride (DB00222) Hydralazine (DB01275) Hydrochlorothiazide (DB00999) Insulin aspart (DB01306) Insulin detemir (DB01307) Insulin glargine (DB00047) Insulin human (DB00030) Lisinopril (DB00722) Metformin (DB00331) Metoprolol (DB00264) Pioglitazone (DB01132) Ramipril (DB00178) Repaglinide (DB00912) Reserpine (DB00206) Rosiglitazone (DB00412) Terazosin (DB01162) Triamterene (DB00384) Valsartan (DB00177)
NCT00641043	Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone	Treatment	Linagliptin (DB08882) Pioglitazone (DB01132)
NCT00598793	Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy	Treatment	Insulin aspart (DB01306) Insulin glargine (DB00047) Metformin (DB00331) Pioglitazone (DB01132)
NCT00086502	Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00736099	Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM	Treatment	Linagliptin (DB08882) Pioglitazone (DB01132)
NCT00121667	Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Saxagliptin (DB06335)
NCT00138554	Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes	Treatment	Pioglitazone (DB01132) Vildagliptin (DB04876)
NCT00396227	Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone	Treatment	2,4-thiazolidinedione (DB11898) Pioglitazone (DB01132) Rosiglitazone (DB00412) Vildagliptin (DB04876)
NCT00106808	Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes	Treatment	Muraglitazar (DB06510) Pioglitazone (DB01132)
NCT00328627	Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.	Treatment	Alogliptin (DB06203) Pioglitazone (DB01132)
NCT00372060	MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)	Treatment	Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00397631	Initial Combination With Pioglitazone Study (0431-064)	Treatment	Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00484198	Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus	Treatment	Pioglitazone (DB01132)
NCT00532935	MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00541450	A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00637273	A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)	Treatment	Exenatide (DB01276) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00676338	Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)	Treatment	Exenatide (DB01276) Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00722371	MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT00789750	Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus	Treatment	Colesevelam (DB00930) Pioglitazone (DB01132)
NCT00885352	Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)	Treatment	Glipizide (DB01067) Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT01028391	30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)	Treatment	Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT01076075	A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)	Treatment	Gliclazide (DB01120) Glimepiride (DB00222) Metformin (DB00331) Pioglitazone (DB01132) Sitagliptin (DB01261)
NCT01106131	Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin	Treatment	Lobeglitazone (DB09198) Pioglitazone (DB01132)
NCT01156597	Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	Basic Science	Pioglitazone (DB01132)
NCT01225081	A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients	Treatment	Ipragliflozin (DB11698) Pioglitazone (DB01132)
NCT01894568	A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment	Treatment	Insulin glargine (DB00047) Insulin peglispro (DB11567) Pioglitazone (DB01132)
NCT02787551	Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period	Treatment	Albiglutide (DB09043) Dulaglutide (DB09045) Exenatide (DB01276) Insulin glargine (DB00047) Liraglutide (DB06655) Lixisenatide (DB09265) Metformin (DB00331) Pioglitazone (DB01132)